Rhythm Pharmaceuticals, Inc. (RYTM): EBITDA
-$191.52M
Year ended 2025-12-31
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$191.52M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$264.80M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$183.46M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$178.26M | n/m | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | -$169.24M | n/m | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | -$135.88M | n/m | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | -$145.17M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$77.97M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$32.19M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$25.76M | n/a | 2019-03-08, From 2016-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | -$191.52M | n/m |
| Lifevantage Corp (LFVN) | 2026-06-30 | $8.87M | -42.2% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | -$9.09M | n/m |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$159.35M | n/m |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | -$156.61M | n/m |
| Liquidia Corp (LQDA) | 2025-12-31 | -$49.85M | n/m |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $48.24M | +13.5% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$224.0K | n/m |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $48.45M | n/m |
Compare RYTM, LFVN, CYRX, PHAT side by side · Screen every company in Pharmaceutical Preparations ↗